Criteria on Evaluating Alternative Solutions:
- Cost
- Effectiveness/Efficacy
- Biocompatibility
- Biodegradability
- Ease of Use
- Safety
- Time Active in System
- Time Present in System
- Ease of Access
Weighting Formula:
Weighting Formula
|
Cost
|
Effectiveness
|
Biocompatibility
|
Biodegradability
|
Total=100%
|
15%
|
20%
|
10%
|
5%
|
Details on Each
Criteria
|
Cost of procedure to make the materials (drug,
etc.) used in the procedure; Cost to store them; Cost of the input (syringes,
machinery). The solution with the lowest cost will have the highest ranking.
|
How effective the drug is as well as the
procedure to deliver the drug
|
Are there any reactions/side effects affecting
the body due to the drug?
|
Is the drug harmful when treated in the body?
Any radioactivity?
|
Ease of Use
|
Safety
|
Time active in system
|
Time present in system
|
Ease of Access
|
5%
|
20%
|
15%
|
5%
|
5%
|
Is there specific instruments or medical equipment, such as UV fluids,
syringes, machinery, that will be utilized for the procedure?
|
Safety is an important factor in determining
whether the solution is viable for general use or only for certain
demographics.
|
How the long the drug can be activated to work
and how long the drug actually works
|
How long the microbubbles and drugs stay in
the system that is inactive to the primary purpose
|
Does it require special containers to store
and transfer, such as temperature- or radiation-sensitive containers?
|
Criteria Evaluation:
Criteria Evaluation (Out of 5.0):
|
1 (least favorable)
|
3 (moderately favorable)
|
5 (most favorable)
|
|||||
Alternative
Solutions
|
Cost (15%)
|
Effectiveness (20%)
|
Biocompatibility (10%)
|
Biodegradability (5%)
|
Ease of Use (5%)
|
|||
1) Adjust the number and positioning of the microbubbles in order to
rupture the capsule
|
5
|
3
|
4
|
3
|
4
|
|||
2) Incorporate antibodies throughout the polymer shell of microbubbles
|
3
|
3
|
3
|
3
|
4
|
|||
3) Composite materials for coating the microbubbles
|
2
|
2
|
4
|
3
|
2
|
|||
4) Use of Polylactic Acid
|
3
|
3
|
4
|
3
|
3
|
|||
5) Albumin and other drugs cross linked with microbubbles
|
4
|
4
|
4
|
2
|
4
|
|||
6) Liposomes and Microbubbles together
|
3
|
3
|
4
|
3
|
4
|
|||
Alternative
Solutions
|
Safety (20%)
|
Time active in system (15%)
|
Time present in system (5%)
|
Ease of Access (5%)
|
Total Weighted Score Out of 5.0
|
|||
1) Adjust the number and positioning of the microbubbles in order to
rupture the capsule
|
3
|
3
|
3
|
3
|
3.45
|
|||
2) Incorporate antibodies throughout the polymer shell of microbubbles
|
4
|
2
|
2
|
3
|
3.05
|
|||
3) Composite materials for coating the microbubbles
|
4
|
4
|
3
|
3
|
3.05
|
|||
4) Use of Polylactic Acid
|
4
|
4
|
3
|
3
|
3.45
|
|||
5) Albumin and other drugs cross linked with microbubbles
|
4
|
4
|
3
|
4
|
3.85
(most favorable) |
|||
6) Liposomes and Microbubbles together
|
2
|
4
|
3
|
2
|
3.05
|
|||
No comments:
Post a Comment